Survodutide: The Dual Agonist Targeting Both Weight and Liver Fat

You go for your annual check-up and the blood work comes back flagged. Your liver enzymes are elevated. Your doctor mentions something about fatty liver disease, possibly MASH, and suggests you lose some weight. You have heard this before. But what you have not heard is that a single medication could address both problems at once.

That is the idea behind survodutide, a once-weekly injection being developed by Boehringer Ingelheim and Zealand Pharma. It activates two hormone receptors simultaneously: GLP-1 and glucagon. The GLP-1 component reduces appetite and improves blood sugar, much like existing medications such as semaglutide and tirzepatide. The glucagon component does something those drugs do not. It ramps up fat burning in the liver.

Phase 2 data shows up to 18.7% weight loss at 46 weeks. A separate trial in patients with MASH showed 62% liver fat reduction. The FDA has granted it Breakthrough Therapy Designation for MASH. Phase 3 results from the SYNCHRONIZE programme are expected in the first half of 2026.

This article breaks down how survodutide works, what the trial data shows, how it compares to other medications, and what the timeline looks like for patients in Singapore.

How survodutide works: the glucagon difference

Most weight loss medications in development target some combination of GLP-1 and GIP receptors. Survodutide takes a different approach. It pairs GLP-1 with glucagon.

GLP-1 receptor activation does what you would expect from this drug class: it reduces appetite, slows gastric emptying, enhances insulin secretion, and signals satiety to the brain. These are the same effects you get from semaglutide or tirzepatide.

Glucagon receptor activation is where survodutide separates itself. Glucagon increases energy expenditure in the liver, promotes fat oxidation, and enhances thermogenesis. In simpler terms, the glucagon component tells your liver to burn more fat for energy instead of storing it.

This dual mechanism is why survodutide shows such strong liver fat reduction data. The glucagon receptor specifically targets hepatic fat metabolism, which makes the drug particularly relevant for patients who have both obesity and fatty liver disease.

Structurally, survodutide is a 29-amino acid peptide based on the glucagon sequence, modified at several positions to also activate GLP-1 receptors. A fatty acid side chain extends its half-life enough for once-weekly dosing, similar to how semaglutide works.

Phase 2 weight loss results

The Phase 2 obesity trial was published in The Lancet Diabetes and Endocrinology in February 2024. It enrolled 387 adults with a BMI of 27 or higher, without type 2 diabetes, and ran for 46 weeks.

Four survodutide doses were tested against placebo:

When measured by actual dose received (accounting for dose adjustments), the 4.8 mg group achieved up to 18.7% mean weight loss, with 40% of participants losing 20% or more of their body weight. At the top dose, 83% lost at least 5%, 69% lost at least 10%, and 55% lost at least 15%.

The trial had a significant dropout problem. Only 60.4% of participants completed the 46-week treatment period, and 24.6% discontinued due to adverse events (compared to 3.9% on placebo). Most of those dropouts happened during the rapid dose escalation phase, which used two-week intervals in Phase 2. The Phase 3 trials have since switched to four-week intervals with the option to pause and restart, which should improve tolerability.

The liver fat data: why survodutide stands out

The most distinctive data for survodutide comes from a Phase 2 trial in patients with MASH (metabolic dysfunction-associated steatohepatitis, formerly known as NASH), published in the New England Journal of Medicine in June 2024.

This trial enrolled adults with biopsy-confirmed MASH and fibrosis stages F1-F3. After 48 weeks:

MASH resolution (without worsening fibrosis):
- 2.4 mg dose: 47%
- 4.8 mg dose: 62%
- 6.0 mg dose: 43%
- Placebo: 14%

Liver fat reduction:
- The 6.0 mg group showed a 62% mean reduction in liver fat from baseline (compared to 5.7% with placebo)
- 57-67% of participants across dose groups achieved at least a 30% reduction in liver fat

Based on this data, the FDA granted survodutide Breakthrough Therapy Designation for MASH in October 2024. This designation can accelerate regulatory review once Phase 3 data are available.

For patients who have both obesity and fatty liver disease, this is a meaningful distinction. Current GLP-1 medications like semaglutide do reduce liver fat to some degree, but survodutide's glucagon component appears to produce substantially larger reductions through direct hepatic effects.

Phase 3: the SYNCHRONIZE programme

Survodutide is now in large-scale Phase 3 testing. The SYNCHRONIZE programme includes several trials:

The Phase 3 obesity trials test two doses (3.6 mg and 6.0 mg) against placebo over 76 weeks. Compared to Phase 2, the key design changes are slower dose escalation (four-week intervals instead of two) and flexibility to temporarily pause dosing if gastrointestinal side effects become difficult.

The SYNCHRONIZE-1 topline results will be the most important upcoming data point. If the Phase 2 signals hold up or improve with the optimized escalation and longer treatment duration, survodutide will be positioned for regulatory submission.

Side effects

The side effect profile in Phase 2 was consistent with the GLP-1 class, though rates were higher than what you see with approved medications like Wegovy or Zepbound.

From the Phase 2 obesity trial:

Most gastrointestinal events were mild to moderate and peaked during dose escalation. Serious adverse event rates were actually comparable to or lower than placebo (4.2% vs 6.5%).

The high discontinuation rate in Phase 2 was the main concern. But that trial used an aggressive two-week dose escalation schedule. The Phase 3 programme uses a more gradual four-week schedule with pause-and-restart flexibility, which is expected to reduce dropouts. Whether it actually does will be closely watched when SYNCHRONIZE-1 reports.

For context on how GLP-1 side effects are typically managed, see our guide to common GLP-1 side effects.

How survodutide compares to other pipeline medications

Survodutide is one of several next-generation weight loss drugs in advanced development. It is not trying to be the drug with the highest absolute weight loss. That title will likely go to retatrutide, which showed 24.2% in Phase 2 and 28.7% in Phase 3.

Survodutide's positioning is different: it is the strongest cardiometabolic drug with liver-specific benefits. The combination of meaningful weight loss (15-19% in Phase 2, potentially more in Phase 3) plus dramatic liver fat reduction and MASH resolution gives it a distinct profile, particularly for patients with fatty liver alongside obesity.

These are cross-trial comparisons with different populations and durations. Direct head-to-head data does not exist for most of these drugs.

What this means for Singapore patients

Survodutide is not available anywhere yet. It is still in Phase 3 trials, with no regulatory filing made as of February 2026.

Based on the expected timeline:

• SYNCHRONIZE-1 topline results: first half of 2026
• Potential FDA filing: late 2026 or 2027, depending on Phase 3 results
• Potential FDA approval: 2027-2028 at the earliest
• HSA (Singapore) approval: typically 12-24 months after FDA, so roughly 2028-2030

For patients in Singapore right now, the available GLP-1 options are semaglutide (both injectable Wegovy and oral Rybelsus) and tirzepatide (Mounjaro). These are proven treatments with extensive safety data.

If you have concerns about fatty liver disease alongside weight loss goals, talk to your doctor. Current GLP-1 medications do provide some benefit for liver fat, even if survodutide's data in this area looks stronger. The most important step is getting started with a treatment that is available and monitored properly.

Frequently asked questions

What is survodutide?

Survodutide is a once-weekly injectable medication being developed by Boehringer Ingelheim and Zealand Pharma. It activates both GLP-1 and glucagon receptors, targeting weight loss and liver fat reduction simultaneously. It is currently in Phase 3 trials and is not yet approved for use anywhere.

How much weight loss does survodutide produce?

In the Phase 2 trial, the highest dose (4.8 mg) produced 14.9% weight loss at 46 weeks using planned treatment analysis, and up to 18.7% when measured by actual dose received. Phase 3 data from the SYNCHRONIZE programme will provide more definitive results.

What makes survodutide different from Wegovy or Zepbound?

Survodutide adds glucagon receptor activation to the GLP-1 pathway. This glucagon component drives liver fat reduction. In a MASH trial, survodutide reduced liver fat by 62% and resolved MASH in up to 62% of patients. Approved GLP-1 medications do not have this level of liver-specific data.

When will survodutide be available in Singapore?

It is too early to say. Phase 3 results are expected throughout 2026. If those results lead to a successful FDA filing, the earliest possible FDA approval would be 2027-2028. HSA approval would follow, likely placing Singapore availability around 2028-2030.

The bottom line

Survodutide is the furthest-along drug to combine GLP-1 with glucagon receptor activation for weight loss. Its Phase 2 data shows meaningful weight loss (up to 18.7%) and uniquely strong liver fat reduction (up to 62%). The FDA has recognised its potential in MASH with Breakthrough Therapy Designation.

The Phase 3 SYNCHRONIZE results, expected in 2026, will determine whether those signals hold up in larger populations with optimised dosing. If they do, survodutide could become the first treatment to address both obesity and MASH in a single injection.

It is not available yet, and it will be years before it reaches Singapore. In the meantime, proven GLP-1 treatments are available now and deliver substantial weight loss with well-understood safety profiles.

Survodutide is an investigational drug not approved by any regulatory authority. The clinical trial results discussed are from published peer-reviewed studies but may not reflect final outcomes. Weight loss results vary by individual. This article is for informational purposes only and does not constitute medical advice. Consult your doctor before starting any medication. Trimly is a MOH-licensed telehealth clinic (HCSA License R/25M0505/MDS/001/252).